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Glycogen, a branched polymer of glucose, is well known as a cellular reserve of metabolic energy
and/or biosynthetic precursors. Besides glucose, however, glycogen contains small amounts of cova-
lent phosphate, present as C2 and C3 phosphomonoesters. Current evidence suggests that the phos-
phate is introduced by the biosynthetic enzyme glycogen synthase as a rare alternative to its normal
catalytic addition of glucose units. The phosphate can be removed by the laforin phosphatase, whose
mutation causes a fatal myoclonus epilepsy called Lafora disease. The hypothesis is that glycogen
phosphorylation can be considered a catalytic error and laforin a repair enzyme.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glycogen synthase (EC 2.4.1.11) transfers glucose moieties from
its substrate UDP-glucose to form a-1,4-glycosidic linkages at the
growing, non-reducing ends of a glycogen molecule ([1]; Fig. 1).
The ideas presented in this article had their origins in recent work
from my laboratory that is described in three papers [2–4]. We
showed that glycogen synthase rarely incorporates the
b-phosphate of UDP-glucose into glycogen [4]. We also showed
that the phosphate could be released by the action of the laforin
phosphatase [2]. The hypothesis to be explored is that the incorpo-
ration of phosphate into glycogen is a catalytic error and that
laforin acts as a repair or damage control enzyme.
2. Enzyme speciﬁcity and side-reactions
In organic chemistry, yields can be low and side reactions prob-
lematic. In nature, enzymes have evolved to accelerate chemical
reactions so as to permit a coherent pattern of chemical intercon-
versions, fast enough and accurate enough, to fulﬁll the needs of
the cell [5]. The kinetic properties of enzymes ensure proper ﬂuxes
through complex metabolic networks. How good must an enzyme
be, in terms of its speciﬁcity and its ability to avoid unwanted side
reactions? This question needs to be elaborated before addressing
the speciﬁcs of glycogen phosphorylation and the hypothesis for-
mulated above.
Discussion of enzyme speciﬁcity is often directed at selectivity
for substrates, the degree of promiscuity, and immediately distinc-
tion must be made between enzymes that have seemingly evolved
to catalyze one particular reaction, of which glycogen synthase
might be considered an example, and enzymes, such aschemical Societies. Published by Ecytochrome P450s [6] or alcohol dehydrogenases [7] whose
evolved function is to act on a variety of substrates. The latter
enzymes are not promiscuous and rather are multispeciﬁc or
broad-speciﬁcity enzymes [6]. It may be difﬁcult or impossible to
deﬁne unique physiological substrates and products. However,
even enzymes viewed as having evolved to mediate a single reac-
tion can be capable of catalyzing other interconversions. There is
indeed a substantial literature on this concept of catalytic promis-
cuity which is by no means a rare phenomenon [6]. Such alternate
reactions may even be physiologically signiﬁcant, and maintained
through evolution, or alternatively they can simply be incidental
due to the chemistry of the catalysis. Enzymatic promiscuity is
viewed as critical for the evolution of new activities.
In a cell, the promiscuous activity of an enzyme towards an
alternate substrate can be considered a side reaction. Another
example of a side reaction, more in keeping with experimental
organic synthesis, would be the generation of alternative products
from the same substrate. For example, many phosphokinase
enzymes are capable of hydrolyzing their co-substrate, usually
ATP, to generate ADP and inorganic phosphate [8]. Similarly, the
glucosyltransferase glycogenin, whose function is to transfer
glucose from UDP-glucose to form a priming oligosaccharide for
glycogen synthesis, can hydrolyze its substrate UDP-glucose to
generate UDP and glucose [9]. As explained below, the introduction
of phosphate into glycogen may fall into this category of side
reaction.
3. Catalytic errors
When is a side reaction an error? Semantics as well as science
enter into answering this question. The idea of an ‘‘error’’ requires
that there is a ‘‘correct’’ outcome. Much discussion of catalytic
errors has addressed the biosynthesis of information-rich biopoly-
mers, like DNA [10], RNA [11] and proteins [12], for which alsevier B.V. All rights reserved.
Fig. 1. Model of glycogen structure and polyglucosan formation. Glycogen is
depicted as being composed of successive tiers of polyglucose chains of average
length 13 residues. The inner B chains would have on average two branches while
the outer A chains would be unbranched. Normal glycogen synthesis, mediated by
glycogen synthase (GS) and branching enzyme (BE), adds glucose moieties from
UDP-glucose to the non-reducing ends of the molecule and introduces the
branchpoints (grey chains; upper arrow). In the proposed rare side reaction (lower
arrow), glucose-phosphate is transferred instead of glucose with the formation of
UMP. The accumulation of covalent phosphate in glycogen is normally opposed by
the action of the laforin phosphatase (LF). In the absence of active laforin, as in
Lafora disease, phosphate accumulates in the glycogen leading ultimately to
structural disturbances, the formation of poorly branched polyglucosan and the
insoluble deposits of Lafora bodies.
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ent base or amino acid, not directed by the coding polymer, is
incorporated. Such events can be considered promiscuous sub-
strate selection, a side-reaction, even though all three of these syn-
theses are mediated by especially complex enzymatic machines.
For all three processes, sophisticated editing and/or repair mecha-
nisms exist to improve the ﬁdelity of polymer production. For DNA
synthesis, the rationale is especially compelling: misincorporation
of a base in DNA can change the genetic blue-print of the cell and
would be perpetuated through cell division. Special mechanisms
have evolved to ensure accuracy in DNA synthesis and elaborate
repair processes also exist. In this example, most people would
agree that production of a new DNA molecule not faithfully repro-
ducing the sequence of the priming strand is indeed an error, that
there is an identiﬁable ‘‘correct’’ reaction. Compared with errors in
DNA, mistakes in the synthesis of individual RNA or protein mole-
cules obviously have a less deleterious impact but, even so, mech-
anisms exist to minimize their occurrence. How does glycogen
phosphorylation compare with such processes?
4. Glycogen, glycogen phosphorylation and Lafora disease
Glycogen, a branched polymer of glucose, serves as a reservoir
of glucose, synthesized in times of nutritional plenty for use in
times of need [1]. Glycogen isolated from biological sources is
polydisperse and does not have a unique structure. A popular mod-
el of the glycogen molecule envisions successive tiers of chains
with an average length of 13 glucose residues [13,14]. Internal
chains would have on average two branch points while the outer-
most tier would consist of unbranched chains (Fig. 1). The bulk
synthesis of glycogen requires the action of two enzymes, glycogen
synthase, mentioned above, and the branching enzyme which
introduces the a-1,6-glycosidic linkages that form the branch
points. The structure of glycogen is dictated by the kinetic proper-
ties of these two enzymes but in a stochastic rather than a precise
way – not every chain is 13 glucoses long and branch points are not
necessarily in identical relative positions in every chain.
Thus, the synthesis of glycogen is profoundly different from the
mechanism by which nucleic acids and proteins are assembled
with a strict conservation of informational content. Can we thenassert that there is a ‘‘correct’’ glycogen product? Obviously not
in the same way as is possible for nucleic acids and proteins but
a number of genetic diseases of glycogen metabolism are informa-
tive on this point. Though rare, mutations in several different genes
cause a series of glycogen storage diseases or glycogenoses [15]. In
some cases, aberrant glycogen structures are formed that contrib-
ute to the pathology of the disease. For example, mutations in the
branching enzyme gene cause Andersen or adult polyglucosan
body diseases in which, as could be predicted, the glycogen formed
has fewer branches than normal, leading to a less soluble polymer
(sometimes called polyglucosan) that forms insoluble deposits. It
would seem reasonable to consider polyglucosan to be an imper-
fect or even incorrect product of the glycogen synthetic pathway.
The most important constituent of glycogen is glucose which of
course underlies its metabolic function. Since the 1980s, however,
it has been recognized that glycogen contains trace amounts of
phosphate [16–18], 1 phosphate per 500 to 1500 glucoses in mus-
cle glycogen [2,3]. In mice, this level of phosphorylation is invari-
ant with age [3]. From analyses of rabbit muscle glycogen, the
phosphate was found to exist as phosphomonoesters at C2 and
C3 of glucose residues [4]. For many years, the origin and function
of the phosphate was obscure. Recently, however, Tagliabracci
et al. [4] reported that in vitro the normal biosynthetic enzyme,
glycogen synthase, was capable of introducing phosphate that
originated as the b-phosphate of its substrate UDP-glucose. Phos-
phate incorporation was infrequent compared with the normal
addition of glucose residues, 1 phosphate for every 10,000 glu-
coses. It was proposed that phosphate was introduced as glu-
cose-phosphate in a side reaction mediated by glycogen
synthase, with concomitant formation of UMP rather than UDP.
The reason for the disparity between the rate of phosphate incor-
poration by glycogen synthase and the steady state glycogen phos-
phorylation state is likely explained by the fact that individual
glycogen molecules undergo multiple rounds of synthesis and
degradation, and phosphate can accumulate. Phosphate content
depends not only on the synthetic rate but also the relative rates
of glucose and phosphate removal.
Worby et al. [19] ﬁrst reported that the laforin phosphatase
could hydrolyze phosphate from amylopectin, a branched polysac-
charide from plant starch which has a similar chemical structure to
glycogen and which contains C3 and C6 phosphomonoesters
[20,21]. They were unable to demonstrate dephosphorylation of
liver glycogen. Subsequently, Tagliabracci et al. [2] demonstrated
release of the phosphate from muscle glycogen by laforin. Laforin
is, by amino acid sequence, a member of the dual speciﬁcity family
of protein phosphatases (DSP; [22]). Laforin is also the only phos-
phatase in mammalian genomes that, in addition to a DSP domain,
has an integral carbohydrate binding module, of the CBM20 sub-
family [23]. Mutation of the CBM20 abolishes the ability of laforin
to bind to and to dephosphorylate glycogen [2]. Laforin, which is
encoded by the EPM2A gene, was ﬁrst identiﬁed in connection with
a neurological disorder called Lafora disease, a fatal progressive
myoclonus epilepsy with typical onset in the teenage years
[24–27]. Roughly half of the cases of Lafora disease result from
mutations in the EPM2A gene. A characteristic of Lafora disease is
the presence of insoluble deposits, called Lafora bodies, in many
tissues, including muscle, liver, heart and brain. The major constit-
uent of Lafora bodies is poorly branched glycogen, polyglucosan. In
a mouse model of Lafora disease in which the Epm2a gene is dis-
rupted, an increase in glycogen phosphorylation was observed,
suggesting that laforin dephosphorylates glycogen also in vivo
[2]. As the Epm2a/mice aged, the increased glycogen phosphate
correlated with disturbances in glycogen structure, decreased
branching frequency, and decreased solubility in water, paralleling
the formation of Lafora bodies in the mice [3]. Increased phosphate
content has also been reported in Lafora bodies from Lafora
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between the increased glycogen phosphorylation and the de-
creased branching frequency. There is, though, an emerging sense
that Lafora disease might be a type of glycogenosis.
5. Is laforin a repair or damage control enzyme?
Excessive accumulation of phosphate in glycogen is associated
with structurally malformed glycogen, and so perhaps the side
reaction of glycogen synthase responsible for the introduction of
phosphate can be considered a catalytic error. There is a parallel
with errors in nucleic acid synthesis in that infrequent side reac-
tions are involved. Interestingly, for glycogen synthase, the error
rate of 104 is within the range of 103–106 reported for single
base substitutions by proofreading-defective DNA polymerases
[10]. If hyperphosphorylated glycogen is an aberrant biosynthetic
product, can the enzyme that normally limits glycogen phosphor-
ylation be considered a repair enzyme? Certainly, the absence of
laforin activity leads to a serious pathological outcome in the form
of Lafora disease. The phosphorylation of glycogen, however, dif-
fers from the misincorporation of bases into nucleic acids acids
in that normal glycogen contains a low level of phosphate. Phos-
phate removal by laforin in vivo is not 100% efﬁcient and a basal
level of glycogen phosphorylation appears to be tolerated. It is as
though there is a phosphorylation threshold below which glycogen
structure can remain in an acceptable range. Without laforin activ-
ity, though, the result is devastating and I would argue that laforin
normally acts in a repair or damage control function.
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